Incorporating the AUA/SUO Guideline on Advanced Prostate Cancer into Practice (2023) - English

September 20, 2023

COMPLIMENTARY CME 90-MINUTE VIRTUAL COURSE!

September 20, 2023 | Time: 7:00-8:30 PM EDT


Incorporating the AUA/SUO Guideline on Advanced Prostate Cancer into Practice (2023) is an exciting new educational initiative to update urologists on the most recent clinical guideline for the management of advanced prostate cancer. This course features a Moderator and three other subject matter experts engaging in an interactive, interview-style presentation and discussion.  

Based on the findings from the latest AUA needs assessment in advanced prostate cancer, the AUA has developed this new series of virtual courses to update urologists on the most recent clinical guideline for the management of advanced prostate cancer. This course will review the evidence-based guideline statements that were developed to provide a rational basis for evidence-based treatment of advanced prostate cancer, including disease stages that range from prostate-specific antigen (PSA) recurrence after exhaustion of local treatment options to widespread metastatic disease. 

The webcast will be made available on AUAUniversity and AUA’s YouTube channel for on‐demand viewing for up to one year. Additionally, the audio of the virtual course will be released as an episode on AUA’s very popular podcast.


Acknowledgements:

This educational series is supported by independent educational grants from: 

  • Astellas and Pfizer, Inc.

  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

  • Lantheus Medical Imaging

  • Merck & Co., Inc.

  • Pfizer, Inc.

 

Target Audience

  • Urologists
  • Residents

Learning Objectives

After participating in this educational activity, participants will be able to:

  1. Cite recommendations within the newly amended AUA/SUO Advanced Prostate Cancer Guideline.
  2. Assess the impact of newly approved agents on the management of men with Advanced Prostate Cancer.
  3. Define M0 CRPC and the treatment options.
  4. Identify clinically meaningful endpoints in clinical trials of patients with M0 CRPC.
  5. Describe gaps in the knowledge for treatment and sequencing of agents in the management of CRPC.
  6. Discuss treatment intensification in mHSPC.
  7. Discuss challenges in incorporating AUA/SUO Advanced Prostate Cancer Guideline and management of advanced mHSPC and CRPC into community practice.
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Non-Physician Participation
Course opens: 
08/21/2023
Course expires: 
09/20/2026
Event starts: 
09/20/2023 - 7:00pm EDT
Event ends: 
09/20/2023 - 8:30pm EDT
Rating: 
0

Welcome and Introductions

Pre-test

Segment 1:  PSMA PET Imaging and M0 CRPC

Segment 2:  Hormone Sensitive Metastatic Disease

Segment 3:  Genetic Testing

Segment 4:  MCRPC

Segment 5:  Future Directions

Post-test

Questions and Answers

Wrap-up

 

Incorporating the AUA/SUO Guideline on Advanced Prostate Cancer into Practice (2023) - English will be held virtually on Wednesday, September 20, 2023 from 7-8:30 p.m. EDT

***Instructions***

  1. Click on the TAKE COURSE button.
  2. Click “Start” under "Live Virtual Course" in the Course Progress pane.
  3. Click on the link provided to register in advance for this course.
  4. After registering, you will receive a confirmation email containing information about joining the course. 

EDUCATION COUNCIL DISCLOSURES

PDF iconEducation Council Disclosures

COI REVIEW WORK GROUP DISCLOSURES

PDF iconCOI Review Work Group Disclosures

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

 

Course Director(s)

Stephen Boorjian, MD

has a financial relationship (Consultant or Advisor (Oncology)) with Prokarium;.
has a financial relationship (Consultant or Advisor (Oncology)) with FerGene;.
has a financial relationship (Consultant or Advisor (General Urology)) with Ferring;.
has a financial relationship (Consultant or Advisor (Oncology)) with ArTara;.
Faculty(s)

Michael Cookson, MD,MHA

has a financial relationship (Consultant or Advisor (Oncology)) with Pfizer;.
has a financial relationship (Consultant or Advisor (Oncology)) with Janssen Pharmaceuticals;.
has a financial relationship (Consultant or Advisor (Oncology)) with Prokarium;.
has a financial relationship (Consultant or Advisor (Oncology)) with Lantheus;.
has a financial relationship (Consultant or Advisor (Oncology)) with Pacifice Edge Diagnostics;.
has a financial relationship (Consultant or Advisor (Oncology)) with Nonagen Bioscience Corp.;.
has a financial relationship (Consultant or Advisor (Oncology)) with Bayer Healthcare Pharmaceuticals;.
has a financial relationship (Consultant or Advisor (Oncology)) with Progenics Phamaceuticals, Inc. (Lanthues);.

Todd Morgan, MD

has a financial relationship (Consultant or Advisor (Oncology)) with Myovant Biosciences;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with A3P Biomedial;.
has a financial relationship (Consultant or Advisor (Oncology)) with Tempus;.
has a financial relationship (Scientific Study or Trial (Oncology)) with MDxHealth;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Myriad Genetics;.

Alicia Morgans, MD

has a financial relationship (Consultant or Advisor (Oncology)) with Telix;.
has a financial relationship (Consultant or Advisor (Oncology)) with Advanced Accelerator Applications;.
has a financial relationship (Consultant or Advisor (Oncology)) with BMS;.
has a financial relationship (Consultant or Advisor (Oncology)) with Janssen;.
has a financial relationship (Consultant or Advisor (Oncology)) with Astra Zeneca;.
has a financial relationship (Consultant or Advisor (General Urology)) with Novartis;.
has a financial relationship (Consultant or Advisor (Oncology)) with Progenics ;.
has a financial relationship (Consultant or Advisor (Oncology)) with Pfizer;.
has a financial relationship (Consultant or Advisor (Oncology)) with Clovis;.
has a financial relationship (Consultant or Advisor (Oncology)) with Astellas;.
has a financial relationship (Consultant or Advisor (Oncology)) with Lantheus;.
has a financial relationship (Consultant or Advisor (Oncology)) with Myovant;.
has a financial relationship (Consultant or Advisor (Oncology)) with Dendreon;.
has a financial relationship (Consultant or Advisor (Oncology)) with Sanofi;.
has a financial relationship (Consultant or Advisor (Oncology)) with Genetech;.
has a financial relationship (Consultant or Advisor (Oncology)) with Myriad;.
has a financial relationship (Consultant or Advisor (Oncology)) with Advanced Accelerator Applications;.
has a financial relationship (Consultant or Advisor (Oncology)) with Merck;.
has a financial relationship (Consultant or Advisor (Oncology)) with Genetech;.
has a financial relationship (Consultant or Advisor (Oncology)) with Bayer;.

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning
  • Selection of alternative faculty for specific topic

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Non-Physician Participation
Please login or register to take this course.

Registration for this Live Virtual Course is complimentary.

To join the live course:

  1. Click on the TAKE COURSE button.
  2. Click “Live Virtual Course” in the Course Progress pane.
  3. Click the link to register in advance: https://auanet-org.zoom.us/webinar/register/WN_HeRd9KH3Sqm9-3429U2DJg
  4. After registering, you will receive a confirmation email containing information about joining the virtual course.

Attendee Information & Policies 

AUA Anti-Harassment Policy 

AUA Commitment: AUA is committed to providing a safe and productive meeting environment that fosters open dialogue and the exchange of scientific ideas and is free of harassment and discrimination. All meeting participants are expected to behave professionally and treat others with respect, follow venue rules, and alert AUA staff or security of any dangerous situations or anyone in distress. 

Reporting Harassment: It is the policy of the AUA that all meeting participants will enjoy an environment free from discrimination, harassment or retaliation. Harassing behavior by meeting participants will not be tolerated. If an individual experiences or witnesses harassment, he or she should contact Janet Skorepa, AUA EVP, at jskorepa@AUAnet.org or Maureen E. Cones, Esq., AUA General Counsel, at mcones@auanet.org or use a venue phone and ask for security if he or she feels unsafe. All complaints will be treated seriously and responded to promptly. 

The AUA reserves the right to take any action deemed necessary and appropriate, including refusing or revoking the registration of any individual, without refund, as long as such refusal is consistent with applicable law and AUA policy. 

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the American Urological Association (AUA). 

Consent to Use of Photographic Images: Registration and attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the registrant or attendee's image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities. 

Audio, Video, Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms. 

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the AUA. 

Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, a written request should be submitted at least one month in advance. For additional assistance with your request please call 1-800-908-9414.